Source disclosure: February 10, 2026
Carna Biosciences,Inc. [4572.T]
TOKYO, Feb 18 (Pulse News Wire) – Carna Biosciences,Inc. (4572.T) reported consolidated results for fiscal year 2025 ending December.
0% YoY).
23 billion with an equity ratio of 25.1%.
For the next fiscal year, the company forecasts 03 billion.
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms •Financial results — FY2025/12 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥579M | -9.0% |
| Operating profit | ¥-2,074M | -2144.0% |
| Net profit | n/a | n/a |
Source: TDNet filing · Figures in millions of yen
💬 Help us improve translation quality
Notice any errors in this article? Let us know with one click.